US 12,285,464 B2
Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (NASH)
Ira Tabas, New City, NY (US); Xiaobo Wang, Fort Lee, NJ (US); Omid Farokhzad, Waban, MA (US); and Xiaoding Xu, Malden, MA (US)
Assigned to The Trustees of Columbia University in the City of New York, New York, NY (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
Appl. No. 16/094,111
Filed by The Trustees of Columbia University in the City of New York, New York, NY (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
PCT Filed Apr. 18, 2017, PCT No. PCT/US2017/028109
§ 371(c)(1), (2) Date Oct. 16, 2018,
PCT Pub. No. WO2017/184586, PCT Pub. Date Oct. 26, 2017.
Claims priority of provisional application 62/323,903, filed on Apr. 18, 2016.
Prior Publication US 2019/0255143 A1, Aug. 22, 2019
Int. Cl. C12N 15/113 (2010.01); A61K 9/1271 (2025.01); A61K 9/50 (2006.01); A61K 31/4178 (2006.01); A61K 31/4439 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 38/17 (2006.01); A61K 47/69 (2017.01); A61K 48/00 (2006.01); A61P 1/16 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/17 (2013.01) [A61K 9/1271 (2013.01); A61K 9/5073 (2013.01); A61K 31/4178 (2013.01); A61K 31/4439 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61K 47/6929 (2017.08); A61P 1/16 (2018.01); C12N 15/113 (2013.01); G01N 33/50 (2013.01); G01N 33/6893 (2013.01); A61K 45/06 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01)] 7 Claims
 
1. A method for treating or preventing progression of steatosis to non-alcoholic steatohepatitis (NASH) in a patient in need thereof, the method comprising administering to the patient in need thereof a therapeutically effective amount of an inhibitor of TAZ, where the inhibitor of TAZ is a nucleic acid comprising a sequence complementary to a sequence encoding human TAZ.